1. Home
  2. HCI vs BEAM Comparison

HCI vs BEAM Comparison

Compare HCI & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HCI Group Inc.

HCI

HCI Group Inc.

HOLD

Current Price

$191.36

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.74

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCI
BEAM
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HCI
BEAM
Price
$191.36
$27.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
12
Target Price
$230.00
$48.09
AVG Volume (30 Days)
131.7K
1.6M
Earning Date
11-06-2025
11-04-2025
Dividend Yield
0.84%
N/A
EPS Growth
32.29
N/A
EPS
15.80
N/A
Revenue
$816,578,000.00
$55,701,000.00
Revenue This Year
$19.65
N/A
Revenue Next Year
$9.97
$26.52
P/E Ratio
$12.12
N/A
Revenue Growth
8.75
N/A
52 Week Low
$106.89
$13.53
52 Week High
$210.50
$35.25

Technical Indicators

Market Signals
Indicator
HCI
BEAM
Relative Strength Index (RSI) 57.89 58.29
Support Level $190.72 $26.71
Resistance Level $196.48 $28.70
Average True Range (ATR) 5.63 1.33
MACD 1.27 0.02
Stochastic Oscillator 77.83 68.93

Price Performance

Historical Comparison
HCI
BEAM

About HCI HCI Group Inc.

HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: